BerGenBio

Report Publication Announcement • Feb 3, 2020

BERGENBIO ASA: Invitation to fourth quarter and full year 2019 results presentation and webcast

BERGENBIO ASA: Invitation to fourth quarter and full year 2019 results presentation and webcast

Bergen, Norway, 3 February 2020 - BerGenBio ASA (OSE:BGBIO), will announce its

results for the fourth quarter and full year 2019 on Tuesday 11 February 2020. A

presentation by BerGenBio's senior management team will take place at 10 am CET

at:

Hotel Continental

Stortingsgaten 24/26

Oslo

The presentation will webcast live and the link will be available

at www.bergenbio.com in the section Investors/Financial Reports. A recording

will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in

the section: Investors/Financial Reports from 7:00 am CET the same day.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Lucy Featherstone, Carina Jurs,

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad Phase II oncology clinical development

programme focused on combination and single agent therapy in lung cancer and

leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing

Phase I clinical testing. In parallel, BerGenBio is developing a companion

diagnostic test to identify those patient populations most likely to benefit

from bemcentinib: this is expected to facilitate more efficient registration

trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com